Progressive supranuclear palsy: a brief personalized history

Area of Science:

• Neurology
• Neuroscience
• Pathology

Background:

• Progressive supranuclear palsy (PSP) was first described in 1964.
• Initially considered a Parkinson's disease variant, PSP was established as distinct through electron microscopy.
• Distinctive straight filaments in neurofibrillary tangles differentiate PSP from other neurodegenerative diseases.

Purpose of the Study:

• To delineate Progressive Supranuclear Palsy (PSP) as a distinct neurological entity.
• To identify key pathological and clinical features of PSP.
• To review current understanding of PSP neurochemistry and etiology.

Main Methods:

• Electron microscopy to identify unique pathological markers (straight filaments).
• Clinical observation to characterize pathognomonic symptoms like paralysis of downward gaze.
• Neurochemical analysis to assess neurotransmitter levels (dopamine, acetylcholine).

Main Results:

• Electron microscopy confirmed straight filaments in neurofibrillary tangles, distinguishing PSP.
• Paralysis of downward gaze identified as a key early clinical sign, linked to specific brainstem lesions.
• Neurochemical studies revealed decreased central dopamine and acetylcholine levels in PSP patients.

Conclusions:

• Progressive supranuclear palsy is a unique neurodegenerative disease.
• The etiology of PSP remains unknown.
• Current therapeutic options for PSP are generally ineffective, highlighting the need for further research.